Patents Examined by Aradhana Sasan
  • Patent number: 11981719
    Abstract: The present invention relates to a growth hormone receptor antagonist comprising a growth hormone variant which is modified by substitution of one or more amino acids of growth hormone. Further, the growth hormone receptor antagonist of the present invention may further comprise a long-acting carrier which is fused to the growth hormone variant. The growth hormone receptor antagonist may have strong binding potency to growth hormone receptor and may exhibit a long-lasting antagonistic action.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: May 14, 2024
    Assignee: Alteogen, Inc.
    Inventors: Soon Jae Park, Jaehyeong Ko, Sun-Ah You, Sang Hoon Yun
  • Patent number: 11975007
    Abstract: Antihypertensive agents which are crystalline having a general plate shape may be difficult to formulate as they often do not exhibit good flowability properties. Addition of spray-dried riboflavin surprisingly improves flowability of these agents.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: May 7, 2024
    Assignee: DSM IP ASSETS B.V.
    Inventors: Markus Nowotny, Zdravka Misic
  • Patent number: 11976106
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions and pharmaceutical formulations comprising the polypeptides and polynucleotides of the disclosure and methods of using and producing same are also disclosed.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: May 7, 2024
    Assignee: OPKO BIOLOGICS LTD.
    Inventors: Oren Hershkovitz, Laura Moschcovich
  • Patent number: 11975041
    Abstract: A composition containing cyclo-hispro (CHP) and its use in preventing, alleviating, or treating bone loss diseases are disclosed. The composition contains CHP or a CHP-containing prostate extract.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 7, 2024
    Assignee: NovMetaPharma Co., Ltd.
    Inventors: Hoe Yune Jung, Heon Jong Lee, Do Hyun Lee
  • Patent number: 11963994
    Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: April 23, 2024
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
  • Patent number: 11957769
    Abstract: Sunscreen compositions comprising a dermatologically acceptable carrier and a polyhydroxy fullerene compound are described. The sunscreen compositions can be used to protect a substrate such as the skin of a subject from the effects of ultraviolet radiation.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: April 16, 2024
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Vijay Krishna, Sanjay Anand, Edward Maytin, Stephen Grobmyer
  • Patent number: 11951154
    Abstract: The present disclosure described herein provides compositions with a membrane-penetrating properties and methods for allowing translocation across a membrane without disruption.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: April 9, 2024
    Assignee: FLAGSHIP PIONEERING INNOVATIONS V, INC.
    Inventors: Laura Gabriela Lande, David Arthur Berry
  • Patent number: 11951165
    Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: April 9, 2024
    Assignee: Vaxcyte, Inc.
    Inventors: Jeffery C. Fairman, Jon H. Heinrichs, Wei Chan
  • Patent number: 11951106
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: April 9, 2024
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11945840
    Abstract: The present invention relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore. The invention further relates to a transmembrane pore complex and methods for production of the pore complex and for use in molecular sensing and nucleic acid sequencing applications.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: April 2, 2024
    Assignees: VIB VZW, Vrije Universiteit Brussel, Oxford Nanopore Technologies PLC
    Inventors: Han Remaut, Sander Van Der Verren, Nani Van Gerven, Lakmal Jayasinghe, Elizabeth Jayne Wallace, Pratik Raj Singh, Richard George Hambley, Michael Jordan, John Joseph Kilgour
  • Patent number: 11939361
    Abstract: The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: March 26, 2024
    Assignees: Janssen Pharmaceutica NV, Protagonist Therapeutics, Inc.
    Inventors: Giustino Di Pretoro, Dajun Sun, Gopal Rajan, Geraldine Broeckx, Nathalie Mertens, Shu Li, Felix Lai, Mohammad Masjedizadeh, Anne M. Fourie, Beverly Knight, David Polidori, Santhosh Francis Neelamkavil, Nishit Modi, Ashok Bhandari, Xiaoli Cheng
  • Patent number: 11938184
    Abstract: In alternative embodiments, the invention provides a “triple combination” therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals.
    Type: Grant
    Filed: March 16, 2021
    Date of Patent: March 26, 2024
    Inventor: Gaurav Agrawal
  • Patent number: 11931359
    Abstract: The present invention relates to a method of increasing the bioavailability and/or prolonging ophthalmic action of a drug, the method comprising instilling into the eye an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters having a D50 value of at least 2 micrometer and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometer to 900 nanometer. The present invention further relates to an aqueous suspension comprising reversible clusters of drug loaded nano-resin particles, said clusters have a D50 value of at least 2 micrometers and said drug loaded nano-resin particles have a particle size distribution characterized in that the D90 value is 70 nanometers to 900 nanometers.
    Type: Grant
    Filed: December 5, 2022
    Date of Patent: March 19, 2024
    Assignee: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
    Inventors: Ajay Jaysingh Khopade, Arindam Halder
  • Patent number: 11926463
    Abstract: A bottle, having an antimicrobial property is provided. The bottle has one or more components including a body, a cap, a seal, and a locking ring. One or more of the components of the bottle are treated with an antimicrobial agent or comprise an antimicrobial agent. The antimicrobial is a silver based antimicrobial, a silver-glass antimicrobial, or other antimicrobial agent.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: March 12, 2024
    Assignee: Microban Products Company
    Inventors: Jonathan Robert Clapp, Ivan Wei Kang Ong, Glenner Marie Richards
  • Patent number: 11918629
    Abstract: Provided herein are kits comprised of a first container including a solution of fibrinogen-containing component that includes fibrinogen at a concentration range of about 5 mg/ml to about 30 mg/ml, and having a total protein concentration range of about 15 mg/ml to about 40 mg/ml; and a second container that includes a solution of thrombin-containing component. Further provided are mixtures comprised of fibrinogen and thrombin, calcium ions, and albumin, the mixture being comprised of total protein in a range of about 2.5 mg/ml to about 30 mg/ml, fibrinogen in a range of about 50% to about 80% of total protein, and albumin in a range of more than 0.65 mg/ml to about 3 mg/ml. Further provided herein are methods for preventing or reducing tissue adhesion, and hydrogel materials made of fibrin.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 5, 2024
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Israel Nur, Elena Grimberg, Itai Podoler, Inbar Gahali-Sass, Erez Ilan, Ronen Eavri
  • Patent number: 11919939
    Abstract: The invention provides an isolated peptide containing a motif that binds antiphospholipid antibodies (aPLA) and that is recognized by CD4+ T cells that are able to induce production of antiphospholipid antibodies (aPLA). The present invention further provides methods for detection of aPLA and CD4+ T cells able to induce production of aPLA. The present invention also provides methods for treating the antiphospholipid syndrome (APS).
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: March 5, 2024
    Assignee: Université de Genève
    Inventor: Karim Brandt
  • Patent number: 11918623
    Abstract: A composition of tirzepatide, comprising an agent selected from NaCl and propylene glycol; and dibasic sodium phosphate is provided.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: March 5, 2024
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Christopher Sears Minie, Dinesh Shyamdeo Mishra, Ken Kangyi Qian
  • Patent number: 11912792
    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: February 27, 2024
    Assignee: BicycleTx Limited
    Inventors: Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
  • Patent number: 11911513
    Abstract: Disclosed are a controlled-release dosage form with an absorption window in the upper gastrointestinal tract and a preparation method therefor, wherein the controlled-release dosage form comprises a controlled-release platform and a retention platform. The controlled-release platform is a pharmaceutical composition comprising a tablet core and a coating membrane; and the retention platform holds the controlled-release platform in the oral cavity. The operation steps of the controlled-release dosage form are as follows: placing the controlled-release platform in the retention platform, and fixing the retention platform on matching teeth in the oral cavity; taking out the controlled-release dosage form after 4-24 hours and replacing same with a new controlled-release platform; and re-fixing the retention platform on the matching teeth in the oral cavity to achieve the sustained and stable release of drugs.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: February 27, 2024
    Assignee: SHANGHAI WD PHARMACEUTICAL CO., LTD
    Inventors: Liang Chang Dong, Xishan Chen, Jingmin Shi, Danyong Zhang, Gang Wu
  • Patent number: 11911511
    Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: February 27, 2024
    Assignee: Aragon Pharmaceuticals, Inc.
    Inventor: Geert Verreck